Invitation to Orion’s Capital Markets Day on 22 May 2025

Orion b

45.00 CHF 12.09%

• Charts
• News
• Analysen

Kaufen Verkaufen

ORION CORPORATION
INVESTOR NEWS
22 APRIL 2025 at 9.00 EEST

        
Invitation to Orion’s Capital Markets Day on 22 May 2025

Orion invites analysts, institutional investors, bankers and media representatives to its Capital Markets Day on Thursday 22 May 2025. The event will be held at Event Venue Eliel, at Töölönlahdenkatu 2, Helsinki, Finland.

During the afternoon, Orion’s President & CEO, Liisa Hurme, CFO René Lindell, and other members of the Executive Management Board will discuss Orion’s growth strategy, financial objectives and businesses. Attendees will have the opportunity to ask questions during the event.

Anyone can follow the event via a live webcast at https://orion.events.inderes.com/cmd-2025 starting at 13.00 EEST. The recording of the event will be available at the same address shortly after the event.

The presentation materials will be available on Orion’s website https://www.orionpharma.com/cmd2025 in the morning on 22 May 2025. The language of the event and the materials is English.

Participants will have the opportunity to ask questions during the event. Questions can also be submitted via webcast.

Agenda of Orion’s Capital Markets Day 2025

12:45 EEST        Registration

13:00 EEST        The event and webcast begins

13:05 EEST        Presentations

• Liisa Hurme, President and CEO
• Outi Vaarala, Executive Vice President, Innovative Medicines and Research & Development
• Hao Pan, Executive Vice President, Branded Products
• Q&A
  
  BREAK

• Satu Ahomäki, Executive Vice President, Generics and Consumer Health
• Niclas Lindstedt, Executive Vice President, Animal Health
• René Lindell, CFO
• Q&A

16:30 EEST        Event ends

The program is subject to change. A more detailed agenda will be available at: https://www.orionpharma.com/cmd2025 closer to the event.

Registration

In order to attend the event at the venue, please register at https://orion.events.inderes.com/cmd-2025 by 15 May 2025 at the latest. The number of seats is limited, and seats will be filled in order of registration.

                                                 
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation

tel. +358 10 426 2721 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orionpharma.com

Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.